The effect of Ursodeoxycholic acid on indirect Hyperbilirubinemia in Neonates Treated With Phototherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210222050449N1

Enrollment

130

Registered

2022-09-19

Start date

2022-10-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperbilirubinemia. Disorder of bilirubin metabolism, unspecified

Interventions

Intervention 1: Intervention group: Including 65 infants classified in the intervention group, in addition to phototherapy, UDCA drug at a dose of 10mg / kg.day, was prepared by Dr. Abidi Pharmaceutic

Eligibility

Sex/Gender

All

Age

1 Days to 28 Days

Inclusion criteria

Inclusion criteria: Birth weight between 2500 to 4000 g Exclusive breastfeeding Gestational age between 38 to 41 weeks Infantile age>24 hours Total Bilirubin = 14 to 20 mg/dl Direct Bilirubin > 2 mg/dl

Exclusion criteria

Exclusion criteria: Infants with ABO and RH incompatibility Glucose 6-phosphate dehydrogenase deficiency (G6PD) Direct hyperbilirubinemia septicemia Diseases caused by hyperbilirubinemia (Crigler-Najjar Syndrome, Gilbert syndrome, hypothyroidism / hyperthyroidism, liver diseases) Diabetic mothers infants

Design outcomes

Primary

Measure	Time frame
Decreased serum bilirubin. Timepoint: after 12, 24 and 36 hours. Method of measurement: Serum bilirubin measurement of neonatal blood samples by laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mahshid Mazandarani

Gorgan University of Medical Sciences

mah.mazandarani@gmail.com+98 17 3220 2565

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026